A University of New England pharmacy professor has received a patent for an innovation in the early detection of breast cancer.
Srinidi Mohan's research focuses on a blood marker that can be used to detect the presence of highly aggressive tumors. He says the marker is a reliable indicator for estrogen receptor-negative tumors, the most aggressive types of breast cancer.
Mohan said Wednesday the bio-marker screening could represent a cost-effective option for early detection, monitoring disease progression, measuring treatment outcomes and providing monthly check-ups.
The latest news from around the state
The American Breast Cancer Foundation says about 60,000 women are diagnosed with those tumors each year. They're most prevalent among young women and in African-American women. Chemotherapy is the common treatment for the deadly tumors.